Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Femara shows survival improvement in women with hormone-sensitive early breast cancer
January 12th, 2006
Women with hormone-sensitive early breast cancer who switched to Femara (letrozole tablets) from placebo as part of a landmark trial experienced significant improvements in overall survival, disease-free survival and distant metastases, according to data presented at the 28th annual San Antonio Breast Cancer Symposium in Texas. The analysis represents the first time that an aromatase inhibitor has demonstrated a benefit in starting therapy up to 5 years after the end of a patient taking tamoxifen, another medicine used in the treatment of hormone-related breast cancers. In this new analysis of the landmark MA-17 trial, postmenopausal women who...
Source: Women's Health Weekly (2006-01-12)
|
